Silent myocardial ischaemia: to treat or not to treat?
1Cardiovascular Clinic and Institute, University of Chieti, Italy.
Insights
Silent myocardial ischemia, common in coronary artery disease patients, is linked to adverse outcomes. Further trials are needed to clarify treatment effects on prognosis, especially in asymptomatic individuals.
Area of Science:
- Cardiology
- Ischemic Heart Disease
Background:
- Silent myocardial ischemia is increasingly recognized in patients with coronary artery disease (CAD).
- Prevalence estimates range from 30-70% in patients with angina or prior myocardial infarction, and 2-4% in asymptomatic individuals.
- Interpreting prevalence data requires caution due to test sensitivity, specificity, and population disease prevalence (Bayes's theorem).
Purpose of the Study:
- To review the relationship between silent myocardial ischemia, ischemic burden, and clinical outcomes.
- To evaluate the impact of current therapies on silent myocardial ischemia and prognosis.
- To highlight the need for controlled trials to guide therapeutic strategies.
Main Methods:
- Literature review of studies on silent myocardial ischemia in coronary artery disease.
- Analysis of data linking silent ischemia to adverse clinical events.
- Assessment of evidence for therapeutic interventions.
Main Results:
- Silent myocardial ischemia is associated with adverse outcomes like non-fatal myocardial infarction and cardiac death, particularly in patients with known coronary lesions.
- An association between silent ischemia and sudden cardiac death is observed, though currently considered elusive.
- Therapies including nitrates, beta-blockers, calcium channel blockers, and revascularization can reduce silent ischemia duration, but their prognostic impact remains uncertain.
Conclusions:
- Silent myocardial ischemia is a significant finding in CAD patients, correlating with poor prognosis.
- Current treatments effectively reduce ischemic burden but lack proven impact on long-term outcomes.
- Controlled clinical trials are essential to determine optimal management, especially for asymptomatic subjects.
Abstract:
Silent myocardial ischaemia is now recognized with increasing frequency in patients with coronary artery disease. It is estimated to occur in 30-70% of patients with stable or unstable angina pectoris or with previous myocardial infarction, while, in totally asymptomatic healthy subjects, a prevalence of 2-4% is reported. However, these data must be evaluated with caution, because the predictive value of the tests employed in detecting silent ischaemia, depends on each test's sensitivity and specificity as well as on the prevalence of the disease in the evaluated population (Bayes's theorem). Available data suggest there is an important relationship between silent myocardial ischaemia, total ischaemic burden and adverse clinical outcome (non fatal myocardial infarction and cardiac death), especially in patients with documented coronary lesions. However, an elusive link between silent myocardial ischaemia and sudden cardiac death has currently been observed. Many reports have demonstrated that therapy with nitrates, beta-blockers and calcium channel blockers or revascularization procedures are effective in reducing silent myocardial ischaemia and its duration, but it remains unclear whether these treatments influence prognosis. A resolution of these uncertainties by controlled clinical trials will be necessary in order to choose therapeutic strategies, especially in totally asymptomatic subjects.
Related Concept Videos
01:14Myocarditis III: Medical Management
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care